Investigating National Solutions for Personalised Iodine-131 Radiation Exposure (INSPIRE)
Trial summary:
The aim of the INSPIRE study is to accurately measure the low radiation doses delivered to normal organs received from radioiodine treatment of differentiated thyroid cancer in 150 patients and to assess radiation doses to target tissues and treatment outcome. Patients will undergo standard-of-care radioiodine treatment followed by a series of SPECT/(CT) scans to assess the biodistribution of radioiodine up to 1 week after therapy. This will allow for the calculation of radiation doses to non-target and target tissues. Patients will be recruited from UK sites with an anticipated trial end date of December 2024.
RT QA summary:
All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.
| QA Process | QA Activity | Required for Trial | Additional Details |
|---|---|---|---|
| Pre-Accrual | Facility Questionnaire |  | |
| Outlining Benchmark Case | |||
| Planning Benchmark Case | |||
| Dummy Run | |||
| During Accrual | Individual Case Review | | |
| Data collection | | ||
| Dosimetry | |||
| QA Streamlining | | SEL-I-METRY |
RTTQA contact: RMcorelab@icr.ac.uk
Chief investigator: Kate Newbold (RMH)
Sponsor: Royal Marsden Hospital, RMcorelab@icr.ac.uk